Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S
Department of Internal Medicine, National Cancer Center Hospital, Tokyo.
Jpn J Cancer Res. 1996 Aug;87(8):867-73. doi: 10.1111/j.1349-7006.1996.tb02113.x.
We studied the effect of heavy alcohol intake (ethanol intake > or = 80 g/day for > or = 5 yr) on long-term results in 53 patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) who had undergone curative hepatic resection. Cell proliferative activity in the tumor and non-tumorous liver was also assessed by counting argyrophilic nucleolar organizer region-associated proteins (Ag-NOR) in the resected specimens. Twenty patients (20 males, 0 females) were positive for heavy alcohol intake [AI(+)] and 33 (28 males, 5 females) were not [AI(-)]. All patients were positive for HCV antibody and negative for hepatitis B surface antigen. Carcinoma recurred within 3 to 51 postoperative months in 42 (79.2%) of the 53 patients. The median disease-free survival time was 12.6 mo in the AI(+) group and 25.4 mo in the AI(-) group (P < 0.01). The AI(+) group also had significantly poorer survival than the AI(-) group (P < 0.05, 3-year survival rate: 66.7% vs. 93.5%). HCC tumor in the AI(+) group showed significantly increased proliferative activity compared with that in the AI(-) group (P < 0.05, Ag-NOR number: 2.3 +/- 0.8 vs. 1.9 +/- 0.4). However, there was no significant difference between the numbers of Ag-NORs in non-tumorous liver from these two groups (1.5 +/- 0.2 vs. 1.5 +/- 0.2). Patients with heavy alcohol intake should be followed particularly closely, even if they have received curative surgery, since heavy alcohol intake is closely related to a poor postoperative prognosis.
我们研究了重度酒精摄入(乙醇摄入量≥80克/天,持续≥5年)对53例接受根治性肝切除的丙型肝炎病毒(HCV)相关肝细胞癌(HCC)患者长期预后的影响。通过计数切除标本中嗜银核仁组织区相关蛋白(Ag-NOR)来评估肿瘤及非肿瘤肝脏中的细胞增殖活性。20例患者(20例男性,0例女性)有重度酒精摄入阳性[AI(+)],33例(28例男性,5例女性)无[AI(-)]。所有患者HCV抗体均为阳性,乙肝表面抗原均为阴性。53例患者中有42例(79.2%)在术后3至51个月内出现癌复发。AI(+)组的无病生存期中位数为12.6个月,AI(-)组为25.4个月(P<0.01)。AI(+)组的生存率也显著低于AI(-)组(P<0.05,3年生存率:66.7%对93.5%)。与AI(-)组相比,AI(+)组的HCC肿瘤增殖活性显著增加(P<0.05,Ag-NOR数量:2.3±0.8对1.9±0.4)。然而,两组非肿瘤肝脏中的Ag-NOR数量无显著差异(1.5±0.2对1.5±0.2)。即使接受了根治性手术,重度酒精摄入的患者也应特别密切随访,因为重度酒精摄入与术后预后不良密切相关。